Cerebrolysin: neuroprotective peptide guide

Key takeaways

Cerebrolysin is a preparation of low-molecular-weight peptides and amino acids derived from porcine (pig) brain tissue
It has been tested in over 30 randomized controlled trials across stroke, traumatic brain injury, and Alzheimer’s disease
Approved and prescribed in more than 40 countries (but not the United States)
A 2015 meta-analysis of six RCTs found statistically significant cognitive improvement in mild-to-moderate Alzheimer’s patients
The FDA has not approved cerebrolysin, and its mechanism involves multiple pathways rather than a single drug target

Cerebrolysin is not a single peptide. It is a standardized mixture of brain-derived neurotrophic peptides and free amino acids obtained through enzymatic breakdown of purified porcine brain proteins. The preparation contains peptides smaller than 10 kDa (about 25% of the mixture) along with free amino acids (about 75%).

Manufactured by Ever Neuro Pharma (formerly EBEWE Pharma) in Austria, cerebrolysin has been in clinical use since the 1970s. It is approved as a prescription drug in over 40 countries across Europe, Asia, and Latin America for conditions including stroke recovery, traumatic brain injury, and Alzheimer’s disease.

The concept behind cerebrolysin is straightforward: brain tissue naturally produces neurotrophic factors that support neuron survival and growth. By extracting and concentrating these factors into an injectable preparation, the treatment aims to supplement the brain’s own repair mechanisms after injury or during neurodegeneration.

Among the peptides studied for cognitive function, cerebrolysin has the strongest clinical evidence base. This puts it in different territory from most compounds covered in peptide therapy guides, which tend to rely on animal data and practitioner experience.

How does cerebrolysin work?

Cerebrolysin acts through multiple mechanisms simultaneously, which makes it both promising and difficult to study with the precision the FDA prefers.

The peptide mixture mimics the activity of naturally occurring neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). A 2026 Russian study measured BDNF levels in stroke patients receiving cerebrolysin and found the treatment significantly increased circulating BDNF compared to controls [1].

The key mechanisms include:

Neuroprotection: cerebrolysin reduces neuronal death after ischemic injury by modulating apoptosis pathways. It stabilizes cell membranes and reduces excitotoxicity (damage from excessive glutamate signaling).

Neuroplasticity: the peptide mixture promotes synaptogenesis and dendritic branching, supporting the brain’s ability to rewire around damaged areas. A 2026 systematic review and meta-analysis found cerebrolysin improved functional skill development in stroke patients during rehabilitation [2].

Neurogenesis: animal studies show cerebrolysin stimulates the proliferation of neural progenitor cells. Whether this translates to meaningful neurogenesis in adult human brains remains debated.

Anti-inflammatory effects: cerebrolysin modulates microglial polarization, shifting the brain’s immune cells from a pro-inflammatory (M1) state to a reparative (M2) state. A 2025 review in Neurology and Therapy discussed cerebrolysin’s role in this context [3].

Because it contains multiple active peptides, cerebrolysin works more like a biological therapy than a targeted drug. This multi-mechanism approach may explain its broad effects across different neurological conditions.

Benefits supported by clinical evidence

Stroke recovery

Stroke is cerebrolysin’s most-studied indication, and the evidence has grown stronger in recent years.

A 2026 propensity-matched cohort study published in Translational Stroke Research followed patients who received cerebrolysin after endovascular thrombectomy for acute ischemic stroke. At 12 months, cerebrolysin-treated patients showed better functional outcomes than matched controls [4].

A 2026 meta-analysis published in Brain and Behavior analyzed observational studies of cerebrolysin as an adjunct to mechanical thrombectomy. The analysis found the combination improved neurological outcomes beyond thrombectomy alone [5].

A 2025 multicenter randomized pilot study (ESCAS) published in Stroke tested cerebrolysin combined with speech therapy for post-stroke nonfluent aphasia. The combination group showed faster language recovery than speech therapy alone [6].

A 2025 observational study in Medicina (Kaunas) evaluated cerebrolysin as an adjuvant to standard stroke therapy and reported improved NIHSS scores (a standard measure of stroke severity) in the treatment group compared to standard care alone [7].

The evidence increasingly supports cerebrolysin as a complement to modern stroke interventions (thrombectomy, thrombolysis) rather than as a standalone treatment.

Alzheimer’s disease

A 2015 meta-analysis by Gauthier et al. pooled data from six randomized controlled trials involving 819 patients with mild-to-moderate Alzheimer’s disease. Cerebrolysin treatment produced statistically significant improvements on the ADAS-cog scale (a standard cognitive assessment) compared to placebo, with an effect size comparable to donepezil (Aricept) [8].

A 2022 RCT by Alvarez et al. published in the Journal of Alzheimer’s Disease examined biomarker changes. Patients receiving cerebrolysin plus donepezil showed modulation of amyloid-beta and tau levels in neuronal-derived extracellular vesicles, suggesting the treatment may affect underlying disease pathology rather than just symptoms [9].

A 2020 study by Alvarez et al. found that serum VEGF (vascular endothelial growth factor) levels predicted which patients would respond to cerebrolysin plus donepezil combination therapy, raising the possibility of biomarker-guided treatment selection [10].

Vascular dementia

A 2019 Cochrane systematic review analyzed RCTs of cerebrolysin for vascular dementia. The review found limited evidence of benefit on global clinical impression but noted that available trial quality was mixed [11]. A 2011 multicenter RCT by Guekht et al. (242 patients) had previously shown improvement in clinical global impression and cognitive function over 24 weeks [12].

Traumatic brain injury

A 2013 Phase II double-blind RCT by Chen et al. tested cerebrolysin in 32 patients with mild traumatic brain injury. The treatment group showed significantly faster cognitive recovery at 1 and 3 months post-injury [13].

A 2024 retrospective study of moderate-to-severe TBI patients found improved cognitive and functional outcomes in the cerebrolysin group [14]. A 2024 interventional pilot study further supported the feasibility and potential benefit of cerebrolysin in TBI patients [15].

A 2025 pilot RCT (CLINCH trial) tested cerebrolysin in primary intracerebral hemorrhage, demonstrating safety and feasibility in this new indication [16].

Post-stroke aphasia

The 2025 ESCAS randomized pilot study showed cerebrolysin accelerated language recovery when combined with speech therapy in patients with post-stroke nonfluent aphasia. Published in Stroke, this represents one of the first controlled trials specifically targeting speech recovery [6].

Side effects and safety

Cerebrolysin’s safety profile benefits from decades of clinical use across millions of patients worldwide.

Common side effects reported in clinical trials include injection site pain and swelling (most frequent), dizziness and headache, nausea, and mild agitation or insomnia (particularly with evening dosing).

Serious adverse events in controlled trials have been rare. The Cochrane review of vascular dementia trials found no significant difference in serious adverse events between cerebrolysin and placebo groups [11].

Because cerebrolysin is derived from porcine brain tissue, theoretical concerns about prion transmission have been raised. The manufacturing process includes purification steps designed to eliminate this risk, and no cases of prion disease have been attributed to cerebrolysin in its 50+ year history.

The 2025 CLINCH pilot trial in intracerebral hemorrhage confirmed safety in a patient population where brain swelling is a concern, finding no increased risk of adverse events compared to control [16].

Patients with epilepsy should use cerebrolysin with caution, as some case reports have noted increased seizure frequency. Those with severe renal impairment need dose adjustment.

For general considerations about peptide safety, see our peptide side effects guide and are peptides safe.

Dosage and administration

Cerebrolysin is administered by intravenous (IV) infusion or intramuscular (IM) injection. It is not available orally, as the peptides would be broken down in the digestive system.

Standard clinical dosing protocols vary by indication:

For acute ischemic stroke, protocols typically use 30-50 mL IV daily for 10-21 days, started within 72 hours of onset. The recent thrombectomy studies used 30 mL daily for 21 days [4].

For Alzheimer’s disease, the meta-analyzed RCTs used 10-30 mL IV daily for 4-12 weeks, often in repeated treatment cycles [8].

For traumatic brain injury, the Chen et al. RCT used 30 mL IV daily for 5 days in the acute phase [13].

For post-stroke aphasia, the ESCAS trial used 30 mL IV daily for 21 days combined with speech therapy [6].

Higher doses (above 5 mL) must be administered by slow IV infusion rather than direct injection. The IV route requires medical facility administration, which limits self-use.

For those unfamiliar with injectable peptide administration, our peptide injections guide covers general principles, though cerebrolysin’s IV requirement means clinic-based administration is standard.

Research and clinical trials

Scale and scope of evidence

Cerebrolysin has accumulated a research base that would be the envy of most peptides. Over 30 RCTs have been completed, with sample sizes ranging from 30 to over 1,000 participants. The research spans three continents and includes Cochrane systematic reviews.

Why isn’t it FDA-approved?

The FDA requires demonstration of efficacy for a specific indication through well-designed Phase III trials meeting US regulatory standards. Several factors have slowed US approval. The multi-peptide composition makes the traditional single-molecule approval pathway difficult. Most trials have been conducted in Europe, Asia, and Latin America, and the FDA typically requires trials in US populations. The effect sizes in cognitive improvement are modest (similar to existing Alzheimer’s drugs), making the cost-benefit case harder to make for a new biological product.

On top of that, the FDA’s preference for single-mechanism drugs creates a mismatch with cerebrolysin’s multi-target approach. The regulatory environment may be shifting, but as of 2026, cerebrolysin remains unapproved in the US.

Active research directions

Current research increasingly focuses on cerebrolysin as an adjunct to modern interventional treatments rather than a standalone therapy. The combination with thrombectomy for stroke [4, 5], with donepezil for Alzheimer’s [9, 10], and with speech therapy for aphasia [6] all follow this pattern.

A 2025 review examined cerebrolysin’s role in post-stroke neuroinflammation, focusing on microglial polarization as a therapeutic target [3]. This line of research could eventually lead to biomarker-guided treatment protocols.

How to get cerebrolysin

In countries where it is approved (including most of Europe, Russia, China, South Korea, and many Latin American countries), cerebrolysin is available by prescription for stroke, TBI, and cognitive impairment.

In the United States, cerebrolysin is not FDA-approved and cannot be prescribed through standard channels. Some patients obtain it through international pharmacies or medical tourism. Physicians may be able to access it through compassionate use or expanded access programs for specific patients.

Some functional medicine practitioners and peptide therapy clinics may offer cerebrolysin as part of cognitive optimization protocols. For those exploring evidence-based options for brain health, peptides for cognitive function covers alternatives available through US prescribers.

For general information about accessing peptide treatments, see our guides on how to get peptides prescribed and peptide therapy online.

Frequently asked questions

Is cerebrolysin FDA-approved?▼

No. Cerebrolysin is approved in over 40 countries but not in the United States. The FDA has not granted approval due to the absence of Phase III trials meeting US regulatory standards.

What conditions does cerebrolysin treat?▼

In countries where it is approved, cerebrolysin is prescribed for ischemic stroke recovery, traumatic brain injury, Alzheimer’s disease, and vascular dementia. Clinical trials have also tested it for post-stroke aphasia.

How effective is cerebrolysin for Alzheimer’s?▼

A 2015 meta-analysis of six RCTs (819 patients) found statistically significant cognitive improvement comparable to donepezil (Aricept) [8]. The effect is modest but real, similar in magnitude to existing approved treatments.

Can cerebrolysin be taken orally?▼

No. The peptides in cerebrolysin would be digested in the stomach. It must be given by IV infusion or intramuscular injection. Doses above 5 mL require slow IV infusion under medical supervision.

Is cerebrolysin made from pig brains?▼

Yes. Cerebrolysin is derived from purified porcine brain proteins that are enzymatically broken down into low-molecular-weight peptides and amino acids. The manufacturing process includes purification steps to ensure safety.

How long does a cerebrolysin treatment course last?▼

Typical protocols run 10-21 days for acute conditions (stroke, TBI) and 4-12 weeks for neurodegenerative conditions (Alzheimer’s, vascular dementia). Treatment courses are often repeated every 3-6 months.

Does cerebrolysin have serious side effects?▼

Serious adverse events in clinical trials have been rare. The most common side effects are injection site reactions, dizziness, headache, and nausea. The Cochrane review found no significant difference in serious adverse events between cerebrolysin and placebo [11].

Can I get cerebrolysin in the US?▼

Not through standard prescribing channels. Some patients access it through international pharmacies, medical tourism, or specialized peptide therapy clinics. Discuss options with a physician knowledgeable about peptide treatments.

References

Shchulkin AV, Chernykh IV, Abalenikhina YV, et al. The effect of neuroprotectors on the level of BDNF, tumor necrosis factor alpha and apoptosis markers in acute cerebrovascular accidents. Zh Nevrol Psikhiatr Im S S Korsakova. 2026;126(2):123-129. PubMed
Shmonin AA, Kashaev IK, Luchinin EA, Bakulin GS. The effect of Cerebrolysin on the development of skills in patients after acute cerebrovascular accidents. Zh Nevrol Psikhiatr Im S S Korsakova. 2026;126(2):32-38. PubMed
Chan TYH, Ma BY, Hung TK, et al. Microglial Polarization and Therapeutic Strategies in Post-stroke Neuroinflammation. Neurol Ther. 2025;14(6):2277-2293. PubMed
Staszewski J, Dębiec A, Gniadek-Olejniczak K, et al. Cerebrolysin after Endovascular Thrombectomy in Stroke: 12-Month Functional Outcomes in a Propensity-Matched Cohort. Transl Stroke Res. 2026;17(2). PubMed
Afridi A, Sajjad F, Arshad A, et al. Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Brain Behav. 2026;16(3):e71252. PubMed
Homberg V, Jianu DC, Stan A, et al. Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study. Stroke. 2025;56(4):937-947. PubMed
Kandasamy G, Arumugam V, Orayj K, et al. Evaluating the Effect of Cerebrolysin as an Adjuvant to Standard Therapy in Patients with Acute Ischemic Stroke. Medicina (Kaunas). 2025;61(9). PubMed
Gauthier S, Proaño JV, Jia J, et al. Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-347. PubMed
Alvarez XA, Winston CN, Barlow JW, et al. Modulation of Amyloid-β and Tau in Alzheimer’s Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin and Donepezil. J Alzheimers Dis. 2022;90(2):705-717. PubMed
Alvarez XA, Alvarez I, Martinez A, et al. Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer’s Disease. Int J Neuropsychopharmacol. 2020;23(9):581-586. PubMed
Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;2019(11):CD008900. PubMed
Guekht AB, Moessler H, Novak PH, Gusev EI. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. 2011;20(4):310-318. PubMed
Chen CC, Wei ST, Tsaia SC, et al. Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study. Br J Neurosurg. 2013;27(6):803-807. PubMed
Soto C, Salinas P, Muñoz D, et al. A retrospective study of Cerebrolysin in patients with moderate to severe traumatic brain injury. J Med Life. 2023;16(7):1017-1021. PubMed
Jarosz K, Kojder K, Skonieczna-Żydecka K, et al. The Effects of Neuromonitoring and Cerebrolysin Administration on Outcomes in Patients with Traumatic Brain Injury. J Clin Med. 2024;13(2):353. PubMed
Kobayashi A, Rutkowska K, Gocyla-Dudar K, et al. Safety and feasibility of cerebrolysin in treatment of primary intracerebral hemorrhage (CLINCH) pilot trial. Front Neurol. 2025;16:1602956. PubMed